Core US Patent Expiry for Xarelto
Xarelto (rivaroxaban), made by Bayer and Janssen, has its primary US composition-of-matter patent (US Patent 7,157,456) expiring on December 21, 2024.[1][2] This marks the end of major patent protection, allowing generic entry soon after, assuming no further blocks.
When Can Generics Actually Launch?
Generic manufacturers like Mylan, Sandoz, and Apotex won FDA tentative approval for rivaroxaban versions, but a patent settlement delays US launch until January 1, 2028.[1][3] Bayer agreed to this to avoid litigation, giving them extended market exclusivity. The FDA's 180-day generic exclusivity for first filers starts on that date, potentially flooding the market with low-cost options.
Why the 2028 Delay Despite 2024 Expiry?
Multiple secondary patents cover formulations, uses (e.g., for DVT prevention), and manufacturing processes, listed in FDA's Orange Book up to 2032 in some cases.[2] Challenges via ANDA Paragraph IV litigation led to the 2028 settlement. No generics launch before then without court overrides.
International Patent Timelines
- Europe: Key patents expired in 2023-2024; generics from Teva and others entered markets like Germany by mid-2024.[4]
- Canada: Patents end in 2025, with generics expected shortly after.
- Japan: Protection lasts until 2027.[1]
Bayer's Other Protections
Pediatric exclusivity adds six months to some patents, pushing certain expiries to mid-2025.[2] Ongoing lawsuits could extend this, but the settlement binds major players.
[1]: DrugPatentWatch.com - Xarelto Patents
[2]: FDA Orange Book - Rivaroxaban
[3]: Reuters - Xarelto Generic Settlement
[4]: EMA - Rivaroxaban Generics